View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 31, 2021

OPKO Health concludes subject enrolment in Phase II Covid-19 drug trial

The trial enrolled 171 subjects, slightly higher than the original target of nearly 160 patients.

OPKO Health has concluded subject enrolment in its Phase II REsCue clinical trial of Rayaldee (calcifediol) extended-release capsules to treat mild-to-moderate Covid-19 in the US.

A total of 171 participants were enrolled, including stage 3 or 4 chronic kidney disease (CKD) patients who are at an increased risk of disease progression.

Rayaldee is an extended-release oral form of calcifediol, which is a prohormone of calcitriol, the active form of vitamin D3.

The randomised, double-blind placebo-controlled REsCue trial will assess the safety and efficacy of Rayaldee in subjects with symptomatic Covid-19 in the outpatient setting.

Participants are randomised in a 1:1 ratio to receive Rayaldee or placebo for four weeks and will be followed up for two weeks.

On days one, two and three, subjects in the Rayaldee arm will receive a 300mcg dose daily, which will be followed by 60mcg daily on days four through 27.

This dosing regimen is intended to increase serum total 25-hydroxyvitamin D (25D) to a range between 50ng/mL and 100ng/mL, the company noted.

Achieving the targeted 25D level and time to resolution of disease symptoms are the trial’s primary efficacy goals.

Occurrence of emergency room or urgent care visits, oxygen saturation under 94%, hospitalisation requirement and duration, as well as mechanical ventilation needs are some of the secondary goals.

Secondary endpoints of the trial also include mortality rate and illness severity and duration shown by quality-of-life and biochemical measures.

Top-line results from the Phase II trial are anticipated later this year, OPKO added. The company launched the trial in September 2020.

Rayaldee is currently approved for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 CKD and vitamin D insufficiency in the US.

It is the first-ever drug to obtain approval from the US Food and Drug Administration to increase 25D and reduce blood levels of intact parathyroid hormone.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy